News Japan first approval for GSK’s bepirovirsen for CHB Japan has approved GSK's antisense oligonucleoide Hibsago (bepirovirsen) as a functional cure in chronic hepatitis B virus infection in adult patients
News GSK to quit Stevenage for new R&D site in Cambridge In a major shake-up of its UK operations, GSK is building a brand new R&D centre in Cambridge and transfer operations there from its Stevenage campus.
News J&J's oral IL-23 drug backed for psoriasis in EU J&J's oral psoriasis drug Icotyde heads up the list of new therapies recommended for EU approval at the CHMP's July meeting.
News Nuvalent buy delivers new cancer approval for GSK GSK has its first approval from the $10.6bn takeover of Nuvalent, ROS1+ NSCLC therapy Jideytro, which becomes the company's first lung cancer product.
News GSK abandons cough drug added in $2bn Bellus deal Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning the programme.
News UK experts call for meningitis shots for all 15-year-olds All 15-year-olds in the UK should be offered the meningitis B vaccine following the fatal outbreaks earlier this year, says the JCVI.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.